Recommendations for improving the quality of rare disease registries by Kodra, Yllka et al.
International  Journal  of
Environmental Research
and Public Health
Review
Recommendations for Improving the Quality of Rare
Disease Registries
Yllka Kodra 1,*, Jérôme Weinbach 2, Manuel Posada-de-la-Paz 3 ID , Alessio Coi 4,5 ID ,
S. Lydie Lemonnier 6, David van Enckevort 7 ID , Marco Roos 8, Annika Jacobsen 8 ID ,
Ronald Cornet 9 ID , S. Faisal Ahmed 10, Virginie Bros-Facer 11, Veronica Popa 12,
Marieke Van Meel 13, Daniel Renault 14, Rainald von Gizycki 15, Michele Santoro 4,5,
Paul Landais 2,16, Paola Torreri 1, Claudio Carta 1, Deborah Mascalzoni 17, Sabina Gainotti 18 ID ,
Estrella Lopez 3 ID , Anna Ambrosini 19, Heimo Müller 20, Robert Reis 20, Fabrizio Bianchi 4,5,
Yaffa R. Rubinstein 21, Hanns Lochmüller 22,23 and Domenica Taruscio 1 ID
1 National Centre for Rare Diseases, Istituto Superiore di Sanità, 00162 Rome, Italy; paola.torreri@iss.it (P.T.);
claudio.carta@iss.it (C.C.); domenica.taruscio@iss.it (D.T.)
2 RaDiCo, (The French National Programme on Rare Disease Cohorts), Inserm-UMR S933, National Institute
of Health and Medical Research, Hôpital Trousseau, 75018 Paris, France; jerome.weinbach@radico.fr (J.W.);
paul.landais@umontpellier.fr (P.L.)
3 Institute of Rare Diseases Research, ISCIII, RDR and CIBERER, 28029 Madrid, Spain;
mposada@isciii.es (M.P.-d.-d.-P.); elopez@isciii.es (E.L.)
4 Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy; alessio.coi@ifc.cnr.it (A.C.);
msantoro@ifc.cnr.it (M.S.); fabrizio.bianchi@ifc.cnr.it (F.B.)
5 Fondazione Toscana “Gabriele Monasterio” (FTGM), 56124 Pisa, Italy
6 Patient Advisory Council of RD Connect and Vaincre la Mucoviscidose the French Cystic Fibrosis Patient
Organization, 75013 Paris, France; llemonnier@vaincrelamuco.org
7 Department of Genetics, University Medical Centre Groningen (UMCG), University of Groningen,
9700 RB Groningen, The Netherlands; d.van.enckevort@rug.nl
8 Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; m.roos@lumc.nl (M.R.);
annika.jacobsen.86@gmail.com (A.J.)
9 Amsterdam UMC, University of Amsterdam, Medical Informatics, Amsterdam Public Health Research
Institute, 1105 AZ Amsterdam, The Netherlands; r.cornet@amc.uva.nl
10 Office for Rare Conditions, Royal Hospital for Children, University of Glasgow, Glasgow G51 4TF, UK;
faisal.ahmed@glasgow.ac.uk
11 Patient Advisory Council of RD-Connect and EURORDIS-Rare Diseases Europe, 75014 Paris, France;
virginie.bros-facer@eurordis.org
12 Patient Advisory Council of RD Connect and MCT8-AHDS Foundation, Oklahoma, OK 74464, USA;
veronica_maria_popa@yahoo.com
13 Patient Advisory Council of RD Connect and NephcEurope Foundation,
2411 DW Bodegraven, The Netherlands; mvanmeel@casema.nl
14 Patient Advisory Council of RD Connect and FEDERG, 1200 Brussels, Belgium; daniel.renault34@orange.fr
15 Patient Advisory Council of RD Connect and PRO RETINA Deutschland, 53113 Bonn, Germany;
rainald.vongizycki@charite.de
16 EA2415 Clinical Research Institute, Montpellier University, 34093 Montpellier, France
17 Department of Public Health and Caring Sciences, Centre for Research Ethics & Bioethics (CRB) Uppsala
University, 75122 Uppsala, Sweden; deborah.mascalzoni@crb.uu.se
18 Bioethics Unit, Office of the President, Istituto Superiore di Sanità, 00162 Rome, Italy; sabina.gainotti@iss.it
19 Fondazione Telethon, 20129 Milan, Italy; aambrosini@telethon.it
20 Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, 8010 Graz, Austria;
heimo.mueller@medunigraz.at (H.M.); robert.reihs@medunigraz.at (R.R.)
21 National Library of Medicine/National Institutes of Health, Bethesda, MD 20892-2128, USA;
yaffa.rubinstein@nih.gov
22 Department of Neuropediatrics and Muscle Disorders Medical Center, University of Freiburg Faculty of
Medicine, 79160 Freiburg, Germany; hanns.lochmuller@gmail.com
Int. J. Environ. Res. Public Health 2018, 15, 1644; doi:10.3390/ijerph15081644 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2018, 15, 1644 2 of 22
23 CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST),
08028 Barcelona, Spain
* Correspondence: yllka.kodra@iss.it; Tel.: +39-06-4990-4365
Received: 28 June 2018; Accepted: 26 July 2018; Published: 3 August 2018


Abstract: Rare diseases (RD) patient registries are powerful instruments that help develop clinical
research, facilitate the planning of appropriate clinical trials, improve patient care, and support
healthcare management. They constitute a key information system that supports the activities of
European Reference Networks (ERNs) on rare diseases. A rapid proliferation of RD registries has
occurred during the last years and there is a need to develop guidance for the minimum requirements,
recommendations and standards necessary to maintain a high-quality registry. In response to these
heterogeneities, in the framework of RD-Connect, a European platform connecting databases, registries,
biobanks and clinical bioinformatics for rare disease research, we report on a list of recommendations,
developed by a group of experts, including members of patient organizations, to be used as a framework
for improving the quality of RD registries. This list includes aspects of governance, Findable, Accessible,
Interoperable and Reusable (FAIR) data and information, infrastructure, documentation, training, and
quality audit. The list is intended to be used by established as well as new RD registries. Further work
includes the development of a toolkit to enable continuous assessment and improvement of their
organizational and data quality.
Keywords: rare diseases; patient registry; quality
1. Introduction
In the field of rare diseases (RD), patient registries are a powerful tool that helps develop
clinical research, facilitates the planning of appropriate clinical trials, improves patient care, and
supports healthcare management. The importance of RD registries is demonstrated by European
Union recognition in the document, “EU Council Recommendation of 8 June 2009 on an action in
the field of rare diseases” [1]. Patient registries constitute key information systems that support the
forthcoming activities of European Reference Networks (ERNs) on rare diseases. In fact, according
to Directive 2011/24/EU, a primary aim of ERNs is to “reinforce research (and) epidemiological
surveillance like registries” [2].
A rapid proliferation of RD registries has occurred in recent years and according to Orphanet
(European website providing information about orphan drugs and rare diseases) there are more than
747 RD registries in Europe [3]. Their objectives are extremely diverse, ranging from clinical patient
data management to epidemiology and research goals; each of them are supported by a wide variety
of information systems, ontological standards, data collection and management tools, as well as
governance models.
In response to these heterogeneities, in the framework of RD-Connect project [4], the National
Center of Rare Diseases in Italy coordinated and selected a group of subject matter experts, including
members of patient organizations, with wide experience in the field of RD registries. The objective
of the expert working group was to make a list of recommendations to be used as a framework for
improving the quality of RD registries.
After reviewing several guidelines on RD registries elaborated by EPIRARE (European Platform
for Rare Disease Registries) [5], PARENT Joint Action [6], Neurological Registry Best Practice Guidelines
in Canada [7] and the Agency for Healthcare Research and Quality (AHRQ) [8], the first draft of this
paper elaborated by the Italian National Center of Rare Diseases was presented to the experts and then
discussed with them. The experts were asked to provide their comments on the basis of their skills
and knowledge on specific parts of the article. The experts’ responses were then collected.
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As shown in Figure 1, the quality of registries is a global concern and involves all sequential activities
for running a registry: (1) Governance; (2) data source; (3) data elements, case report form, standardisations;
(4) IT infrastructure complying with FAIR principles (Findable, Accessible, Interoperable, Reusable for
humans and computers); (5) data quality; (6) quality information; (7) documentation (8) training staff;
(9) and data quality audit.
Recommendations laid out here are developed for each topic and each of them is preceded by a
justifying comment.
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urpose [9]. In 1991, another broad definition was provided by Solom n et al., wh defined a registry
as a database of identifiable pers ns containing a clearly defined set of health and emographic data,
collected for a specific public health purpose [10].
, istr definition evolved and it was no longer conceived as a file or dat b se but as
n organised system, highlighting he prospectic characteristic of its design. In fact, the most complete
definition was provided by the Agency for Healthcare Research and Quality (AHRQ) as: «[ . . . ] a
patient registry is an organized system that uses observational study me hods to collect uniform data (clinical
and other) to evaluate specified out omes for a population defined by a particular disease, condition, r exp sure,
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Reco mendation #1: RD registries are an organised information system, based on observational study with
one or several predefined purposes and rules with a long-t rm perspective. We recommend that RD registries not
be limited by geographic area, but have an i ternational vision. In the field of RD, there is a need to identify as
many patien s as possible, and a significant n mber of cases can be identified from a large population. Moreover,
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RD registries should be created and used as a data source for the purpose of performing subsequent or additional
studies related to research, patient care, or public health monitoring.
1.2. Registry Classification
Registries can be classified in different ways in accordance with their objectives. They can
be divided into three categories with multiple subcategories and combinations: (1) Public health
registry (e.g., disease occurrence: estimate incidence and prevalence, temporal trends and geographical
distribution in relation to person, place, time); (2) clinical registry (e.g., the study of natural history of
disease); (3) product registry (e.g., medical devices or pharmaceutical products) and a combination
(e.g., aspects that belong to more than one registry type) [11,12].
Based on geographic coverage, registries can be classified as: population-based registries, which
refer to a geographically defined population and their aim is to register all cases in that population;
and non-population-based registries, which are based on selected bodies, clinical centres or other types
of structures where the population coverage may not be comprehensive [13].
Depending on which disease is under study, a registry can be classified specifically for one disease
(e.g., Neurofibromatosis Registry) or group of diseases (e.g., Registry for Neuromuscular Disease).
Registries are also classified according to the type of drivers: (1) patient-driven or patient
self-reported (only patients provide information); (2) physician-driven or professional-reported (only
physicians provide information) or (3) combination of patient self-report and professional-reported
(information is provided by both patients and their physicians).
In addition, based on the method used for data collection, registries are classified as manual/
paper-based and/or electronic-based. In electronic registries, part of the registry data can be
electronically imported from other data source systems (e.g., omics data from diagnostic laboratories,
or data from the patient’s Electronic Health Records and, of growing importance, data from connected
devices and smartphone applications) with semi-automatically quality controlled via pre-set rules,
avoiding possible manual transcription errors and lowering the burden of manual data entry.
Another category is administrative registry, which collects information for administrative purposes
(e.g., national registry of hospital admission, national registry of causes of death). They usually contain
information from a large range of conditions. This is in contrast with disease-specific registries, which
focus on a single disease or on related groups of diseases and have more clinical background.
Recently, a new registry category, called registry-based randomized controlled trials, has been
included [14]. The advantages of registry based randomized controlled trials include low cost,
enhanced generalizability of findings, rapid consecutive enrolment, and the potential completeness of
follow-up for the reference population [15].
Recommendation #2: In order to fulfill expected objectives, the taxonomic position of the registry should be
clearly defined. It can be classified into several categories according to different criteria (e.g., geographic coverage,
diseases coverage, type of sponsors, methods used for data collection, etc.).
The next subchapters present recommendations for each topics included in Figure 1.
2. Governance
The AHRQ guide [8] defines governance as referring to guidance and high-level decision-making,
including the following key functions: Defining objectives, identifying stakeholders, building the team,
Ethical Legal and Societal Issue (ELSI) and privacy, ensuring sustainability.
2.1. Defining Objectives
A registry should have one main general objective associated with specific secondary objectives.
The objectives need to be specific, sufficiently detailed, and attainable. Clear objectives are essential to
define items to be collected, which patients to include, which ethical and regulatory pathways to go
through, which design of the study to opt for, which analytical and reporting approaches to prepare.
This will ensure that the registry effectively addresses important scientific questions and collects data
Int. J. Environ. Res. Public Health 2018, 15, 1644 5 of 22
that fulfil the precise goal. Attempts to be all inclusive with unclear initial objectives may add cost
but no value, resulting in overly data collection that reduces quality and completeness and finally
does not allow to adequately address important questions. On the other hand, a good registry should
be conceived as agile enough in its intrinsic design to allow addressing new, emerging questions
whenever needed by allowing new data items (or specific forms) to be added over time for specific
secondary research projects and specific registry patient subgroups. This agility will support its overall
sustainability strategy.
Recommendation #3: Define clear objectives and consequently design the structure of the database.
Often, registries start with a single purpose, but can evolve into multiple purposes, addressing the interests of
other collaborators and stakeholders. In RD registries, the objectives could be expanded, although they must be
prioritized and clearly defined.
2.2. Identifying Key Stakeholders Including the Particular Engagement of Patient Representatives
Identification and early engagement of relevant stakeholders is key to success of a patient registry.
Stakeholders include clinicians, patients, family and patient organisations, researchers, and public
authorities (e.g., drug agencies), registry funders or private stakeholders (e.g., drug companies,
foundations, etc.). The inclusion of more stakeholders increases benefits, but can potentially also
complicate decision-making processes. Stakeholders can have conflicting interests and an essential
time-consuming step is aligning the aims of the registry with these interests. It is therefore important
to determine the main objectives and the expected respective contributions with key stakeholders
at an early stage. A key group of stakeholders to consider in the registry governance is patient
representatives. Their inclusion can increased enrolment, collection of non-clinical data such as patient
reported outcomes, sharing of the results with other patients and provision of financial support.
Early inclusion enhances the right of ownership, which also changes their role from passive (patient is
a data subject) to active (patient runs the registry). Indeed, several registries for specific RD have been
initiated by patient groups. Furthermore, the active engagement of patients at all levels of development
ensure that RD registries represent patient needs, increase awareness among all stakeholders of the
existence of the registry and, ultimately, improve the quality and quantity of data collected through
a patient-centered approach [16]. A variety of methods exist on how to consult with patients and
professionals. In the context of the registry, the Dialogue Model appeared feasible to structure the
process of collaboration between stakeholders and patient organizations [17].
Recommendation #4: Engage with all relevant stakeholders, especially patients’ representatives at an early
stage in the implementation of a registry.
2.3. Building the Team
A key strength of the registry is that the staff are required to have different expertise for each aspect
of the registry system which may include a registry leader (with roles such as strategy, relations with the
participating institutions’ administration, financial sustainability, and collaborations); project managers
(with roles such as timelines, milestones, deliverables, reports, communication and budgets); domain
experts or disease clinical experts (with roles such as content of the registry, selecting appropriate
disease variables, endpoints and scoring standards); experts in epidemiology and biostatistics (with
roles such as conception, methods, analysis, interpretation and modeling); database managers (with
roles such as collection, registration, data management and monitoring); IT personnel (with roles
such as information system architects, software developers, back office/helpdesk and bug resolutions,
automation and output and ensure technical interoperability); Ethical Legal and Social Issue (ELSI)
and privacy specialists (with roles such as ensure compliance with legal requirements and data
protection, informed consent); quality assurance experts (with roles such as data quality and quality
assurance of procedures); legal affair specialists (partnership contract with private companies, access
and IP protection and exploitation issues, consortium agreement, confidentiality agreements, etc.) and
administration (e.g., secretarial support). Authorized representatives of the legal entities involved
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in the registry should also be involved in decision making process and informed about strategic
development perspectives as often as possible.
Independent of the size and purpose of the registry, all the expertise described above is required.
However, the team size (number of employers) might differ from case to case; one employer might
cover more than one expertise; it could be internal or external to the day-to-day operation of the registry.
Recommendation #5: Establish a good registry team with clear role and responsibilities for all staff working
members in proportion with the registry’s size, ambitions, and objectives. Identify a registry leader, domain
expert, IT expert and ELSI expert at the start. Either employ an IT person within your registry or setup a
long-term partnership with a commercial company.
2.4. Ethical, Legal and Societal Issue (ELSI) and Privacy
Building a solid framework that addresses Ethical, Legal and Social Issues, along with legal
requirements, including privacy, is a fundamental cornerstone to build a sustainable future-oriented
registry; unfortunately, registry holders are often unfamiliar with these concepts [18].
A registry should be developed in accordance with ELSI principles and rules and in accordance
with the main international applicable ethical guidelines and soft regulations, and appropriate
professional guidelines (e.g., WMA Helsinki declaration 2013, WMA Declaration of Taipei 2016,
Cioms guidelines, Oviedo convention, etc.), even in the absence of explicit legal obligations.
ELSI principles arise from ethical and legal considerations to pursue medical research in a
responsible and respectful way, including inter alia international and local data protection regulations.
Registry owners must be aware of these regulations, but also be conscious that basic principles such
as respect for the individual, for ethical and legal issues, and obligation to informed consent are
not optional (unless there is a national legal basis to allow collection of data). Complying with
international ethical and legal standards is essential to make the registry usable on a larger scale.
Consequently, helping data providers identify relevant ethical and legal requirements and how these
can be addressed is an essential, but frequently neglected, step when removing possible hurdles to
data and sample sharing in the life sciences [19,20]. The most important European law for patient
registries is ‘The General Data Protection Regulation (GDPR)’ [21] that seeks to protect individuals
with regard to processing of personal data and free movement of such data. The regulation, adopted
on 27 April 2016, was officially applied across Europe on 25 May 2018. It replaces the current 1995 data
protection directive 95/46/EC. The GDPR will ensure compliance with local legal requirements within
that country or region; approval should also be obtained from a medical-ethical committee.
Safeguards for patients are not only based on privacy regulations, but also on informed consent
and/or expressed by an ad hoc national law for registries. As already mentioned, consent is not
only a legal requirement in most countries, but is traditionally a mean to inform patients and build a
trustworthy relationship with them, along with inclusion in the planning phase and in the governance
structure of the registries. When informed consent is used, the patient should receive information that
explains the purpose of the registry, what information will be stored, how the data will be used, the
governance of access to the data by third parties and the foreseen access rules, how the patient can
access any data, and how the patient can revoke consent. Consent is often required for publications
and for international projects [22], and there is a need for improving the informed consent process in
international collaborative rare disease research—effective consent for effective research. The GDPR
also enforces in Europe individuals’ rights, such as portability right, the right to object to certain uses,
and the right to withdraw. This means keeping patients updated about policies and uses foreseen in
a registry.
Security measures regarding personal and sensitive data treatment in biomedical and epidemiological
fields in many European countries are already well established and guarantee high-level protection
of privacy. Confidentiality is insured on an operational level (pseudonymization, security measures).
In this specific setting, the GDPR finds a solid environment to easily apply its provisions. To determine
a country’s national guidelines, the relevant national Data Protection Commissioner’s Office should
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be contacted early on in the design of the registry, in relation with the Data Protection Officer of the
legal entity responsible for the registry. It is crucial to ensure privacy of patients’ identities and in
particular efficiently store patient identifiers. This includes pseudonymization of data to ensure that
the patient is protected and double codification if data is shared. When considering data security, it is
also important to formalise a policy document on data custodianship, access, and intellectual property.
This should be set at an early stage via (1) an internal collaboration agreement between all participating
legal entities (i.e., a consortium agreement) and (2) via a publicly accessible database access charter to
inform potentially interested external users (e.g., BaMaRa (the French Rare Diseases Database) users’
charter [23] or I-DSD (International Disorders of Sex Development) standard operating protocol [24]).
Data should only be accessed through secure channels and for specific purposes defined though a
procedure that ensures traceability in order to be accountable for the usage of the data.
A crucial aspect of the registries is transparency. It is paramount that information about registry
policies and operations are public and readily accessible to anyone interested. A good method to
achieve transparency is: (a) the creation of a website of information about registry objectives and
operations, registry information should be available in various media; (b) criteria on the capacity for
sharing and exchanging data with other registries (national and international) supported by FAIR
principles (quality); (c) access rules and duties for accessing parties (including clear intellectual property
and exploitation policies, DTA (Data Transfer Agreement) rules etc.; (d) data security measures,
traceability, informed consent, and its scope (e.g., possibility of secondary use of data)and patient’s
rights implementation).
Recommendation #6: Ensure compliance with (inter-) national and local ethical and legal requirements and
on that basis, develop public policies for accessing maintaining and operating the registry.
2.5. Sustainability
Sustainability is strictly connected to quality. High-quality RD registries have policies in place to
ensure long-term sustainability and low quality registries are more likely to have been set up with few
or no funds [25].
Very often, registries lack funding and resources and budgets are often exhausted by data
collection and processing tasks alone. Few resources are left for maintaining the electronic
infrastructure; performing security audits, quality controls, data analysis, interpretation; and the
reporting and dissemination of important findings oriented towards appropriate medical and
professional communities. In a number of cases, epidemiologists and statisticians are available
on a temporary basis, or different persons are transitorily assigned to provide support on different
occasions. Under these circumstances, a great deal of time has to be spent familiarizing personnel with
the registry data, making temporary personnel far less useful. To the extent possible, funding should
be ensured before the decision to implement a registry is made [10]. Very often, clinicians are likely to
find data input too cumbersome, as it interferes with their routine work.
It is crucial to evaluate the budget early and ensure sufficient funding (and subsequent
fund-raising efforts) for all activities related to the registry, to ensure its sustainability over a period that
needs to be pre-determined. Expenses depend on the scope of the registry, costs for the underlying data
capture tool, overall information system including costs for sensitive health data hosting and security
audits, method of data collection, duration of data collection, number of participating centers, and
process of data validation. Population-based registries, especially in the case of extensive data collection
and/or long-term follow-up, are more expensive and time consuming to implement, compared with
registries based on administrative and health data routinely collected by national, regional and
local health authorities. In fact, population-based registries are demanding in terms of personnel
and financial support, and therefore are very expensive, especially for the validation process of
events, which should be homogeneous across countries so as to produce representative, accurate and
comparable data.
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The development and operation of a registry also requires long-term commitment. In many
cases, the registry can take years to realize its full benefits; years for patient inclusions and years of
longitudinal data collection are needed to answer the questions that the registry is designed to address.
Potential funding sources are pharma and the private sector at large; health care insurers;
public authorities at the regional, national and European levels; patient organizations, professional
associations. Registries can be funded from one or multiple sources. Shared funding mechanisms
between public and private sources are becoming more common. Private-public partnerships have
shown increasing interest in registries, to improve safety monitoring, compare effectiveness goals, and
streamline the costs of drug or disposal development processes [26]. Multi-sponsor registries decrease
the financial burden on each party, secure wider support, and limit financial risks when funding from
one source fails [27].
Recommendation #7: Ensure that the required budgets have been evaluated and that the registry is well
resourced for a pre-defined period. For long-term sustainability, registries should seek funding from multiple,
complementary sources.
3. Data Source
3.1. Definition and Classification
Data source refers to the medical file where the actual data collection takes place and where all
eligible patients are identified.
Data sources are classified as primary or secondary based on their relationship to the registry
purpose. Primary data sources are collected for direct purposes of the registry [8] and are typically
used when the data of interest is not available elsewhere or, if available, is unlikely to be of sufficient
accuracy and reliability. Secondary data sources have already been collected for another purpose
but are used by the investigator to examine a novel research question; in this case, information is
transferred into the registry from existing databases. Examples of secondary data sources include
medical records systems, administrative health insurance claims data, and death and birth records [6].
There are many advantages and disadvantages to using primary or secondary sources.
The primary trade-offs relate to time, resources, and control of the collection of study variables.
Using primary data sources, a researcher can control all aspects of the study methodology; all variables
of interest can be measured. The creation of primary data sources requires wide consensus. They are
in most cases costly and time consuming; however, they can also provide high-quality data. Secondary
data sources are, on the other hand, less costly. They are easier to gather—providing that there is
sufficient legal/regulatory clearance background and willingness of owners to share information.
Secondary data sources may also cover a large geographic area and thus provide the ability to assess
national trends; a disadvantage is that the data may not include all variables of interest [28]. Data from
secondary sources are used either by automatic transfer into the registry or by linkage to other data
sources to create a new, larger dataset for analysis. Data quality control before integration in the
registry database is in both cases an important issue. It is worth emphasizing that the primary data
source for one registry can act later as a secondary data source for another registry.
Recommendation #8: The selection of primary data sources is critical for success of the registry; they provide
data of higher quality than secondary data sources. Before incorporating a secondary data source into a registry,
it is important to consider the legal and ethical feasibility of its incorporation and the potential impact of the
data quality of the secondary data source on the overall data quality of the registry. Primary data sources are
expensive and time consuming, thus, it is important to consider the possibility of reuse of existing data from
secondary sources.
3.2. Selection of Data Sources
Data sources are important windows for bias and their quality should be analyzed and known
before the start of registry activities.
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The most important aspect is their appropriate selection in terms of:
a) quantity:
– representatively (geographic coverage (e.g., number of hospitals/disease expert centers in a
particular region of the country),
– size (e.g., number of patients enrolled for each hospitals) and
b) quality (completeness and capacity to identify patients with clear-cut diagnosis of interest).
With regard to data on rare events, a significant number of cases can be identified from a large
population. Nevertheless, it is known that the ideal quality of cases identification for rare events is
possible when one focuses on a limited population and conducts proper follow up and monitoring.
Therefore, it is important to balance quantity versus quality, which also depends on the objectives
of the registry. For a public health registry that is used to calculate incidence rates of diseases, it is
essential to include all existing patient cases; therefore, quantity is of critical importance. On the other
hand, for clinical registry, the importance of quality in case identification is greater than enrolment of
all existing cases in the study. It is preferable to select data sources that guarantee a satisfactory level
of quality, without the objective of exhaustive geographic coverage.
Data sources should also enroll patients who satisfy so-called inclusion and non-inclusion criteria,
which are a set of conditions that a patient must meet to be eligible for inclusion in a registry.
Generally included are descriptive characteristics (e.g., given molecular diagnosis, stage of disease) or
demographic characteristics (e.g., age, gender, ethnicity) and geographic location (e.g., hospitals in a
particular region of the country). Non-inclusion criteria, on the opposite hand, are those criteria that
disqualify subjects from inclusion in the registry. Inclusion and non-inclusion criteria should therefore
be defined as carefully as possible.
Particular attention should be paid to the ability of the data source to follow-up on included
subjects. The so-called “lost to follow-up” is a critical issue because it may introduce a selection
bias into the registry data. It is important to select data sources with potentially minimal loss of
follow-up data.
Recommendation #9: Provide clear-cut definition of inclusion and non-inclusion criteria. In terms of
geographic coverage, when selecting data sources (e.g., hospitals), it is important to consider representativeness
and ensure a satisfying level of quality in identifying all eligible patients (including the ability of proper
follow-up).
4. Data Elements, Case Report Form, Standardisations
4.1. Definition of Data Elements
A data element is a logical unit of data, which has a name, precise definition, and clear enumerated
code values [29]. The data elements (DEs) that are included depends on the goal of the registry and it
is important to carefully weigh the value of each data element to be included. Reducing the amount
of data collected lowers costs, increases compliance, and improves the proportion of fields that are
accurately completed. Too often, registries fail in their original purpose because information collection
becomes too complex and unmanageable.
Planning linkages with other information systems during the developmental phases of the registry
can eliminate redundant data elements from the system. It is often useful and time well spent to
identify data elements that are essential or absolutely necessary and those that are “optional” or
“desirable”, but may not be considered central to the key study hypothesis [30]. Inclusion of essential
(or core) data elements in registries can enhance registry feasibility and sustainability by providing
meaningful opportunity for sharing of data between registries.
Before deciding on data elements to be included in a registry, registry developers should gain an
overview of the existing validated sources of data available and try to identify developed DEs that can
be reused. Consultations with experts also ensure selection of appropriate DEs. Not only does this
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prevent problems that others have already resolved in defining data elements, but also facilitates data
sharing and consistency. Another essential aspect is the dynamic annotation of the Case Report Form
(CRF), which has an impact on the underlying database structure (coherence rules, automatic quality
controls, conditional sections, and branching logics between DEs).
We identified a number of potential sources of DEs available worldwide:
- National Institute of Neurological Disorders and Stroke for neurological conditions (NINDS) [31].
- National Cancer Institute for Bioinformatics (NCICB) has developed the Common Data Elements
(CDEs) for the cancer field [32]. NCICB stores the CDE in a relational database called CaDSR
(Cancer Data Standards Repository) [33].
- The EPIRARE (European Platform for Rare Disease Registries) project [34] and RD Connect
(integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare
disease research) project [35] developed a minimum data set focused on rare disease registries.
- Translational Research in Europe for the Assessment and Treatment of Neuromuscular Disease
for neuromuscular disorders (TREAT-NMD), including: (1) core data set for Duchenne Muscular
Dystrophy (DMD) national registry [36]; (2) core dataset for international Facioscapular muscular
dystrophy (FSHD) registry [37]; (3) core dataset for international Myotonic Dystrophy (DM1)
registry [38]; (4) Spinal Muscular Atrophy (SMA) Registry Core Data [39].
- Patient-Reported Outcomes Measurement Information System (PROMIS) project created a
web-based resource that features data field banks, case report form banks, and centralized
access to computerized-adaptive testing for some measures [40].
- National Patient-Centered Clinical Research Network (PCORnet) Common Data Model (CDM) [41].
- Clinical Data Interchange Standards Consortium Operational Data Model (CDISC ODM) that
develops data standards to streamline clinical research and enable connections to healthcare [42].
- Medical Data Models (MDM) portal is a meta-data registry for creating, analyzing, sharing and
reusing medical forms. The portal, developed by the Institute of Medical Informatics, University
of Muenster in Germany, maintains a repository of over 780,000 data elements [43].
- The U.S. National Library of Medicine (NLM) maintains a repository of common data elements,
including relevant tools and resources, containing over 20,000 data elements [44].
- The French minimum data set for rare diseases (F-MDS-RD) is a minimum set of DEs agreed for
mandatory collection and reporting at the national level [45].
- Joint Research Centre (JRC), together with The Directorate-General for Health and Food Safety
(DG SANTE) released a Set of Common Data Elements for Rare Diseases Registration [46].
Recommendation #10: The following steps are recommended for defining DEs:
· Determine what data are needed for the purpose(s) of the registry.
· Determine what information models and forms exist that can be reused.
· Determine what data are obtained from primary sources (requiring additional effort to collect) and from
secondary sources (at the risk of lower data quality).
· Determine what data can be derived from other data, rather than being collected separately.
· Determine whether data can be collected and stored as a part of clinical care (thus becoming data from
secondary source).
· Determine whether data can be fed back to assist clinical care.
4.2. Establishment of Case Report Form (CRF) Questions
From a methodological point of view, it is important to distinguish the concept of Case Report
Form (CRF) from DEs. The CRF is the interview questionnaire used to collect registry data and includes
questions and data that the registry intends to collect from its patients. The CRF is a printed, optical or
electronic document designed to record all of the protocol—required information to be reported to the
sponsor on each trial subject [47].
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It is recommended to establish and maintain a library of templates of standard CRF modules
as they are time saving and cost-effective. A CRF Library is offered by the National Institute of
Neurological Disorders and Stroke for neurological conditions (NINDS) Team [48]. Examples of CRF
module are reported in Figure 2.
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4.3. Standardisations
The st ardisation of DEs is a critical part of developing a registry. The alignment of our DEs
with standards (international or national) can be carried out through the use of a coding system,
terminologies, vocabula ies, and ontol gies. The use of standa ds in a registry system is a quality
indicator since this facilitates consiste cy, reu e and seman ic interoperability. The Human Phenotype
Ontology (HPO) and Orphanet Rare Dis ase Ontology (ORDO) are the most important standards
used for phenotype descriptions and disease classification in the field of RD; both are promoted by
International Rare Diseases Research Consortium (IRDiRC). Annotation of registry data with HPO and
ORDO is a key starting point for ensuring interoperability [49,50] and complying with FAIR principles.
Table 1 presents several international standards that are widely used in the health domain.
As mentioned, for each DE, a definition, identification, representation, and permissible values
need to be specified. The definition is important to ensure that the meaning of the data element is
maximally clarified (e.g., a check box for a disease may only be checked if presence of this disease has
been professionally assessed). Identificati n is id lly done throug the use of international standards,
such as Logical Observ tion Identifiers Names and Codes (LOINC). Representation i cludes the
specification of data types; for example, numerical data elements, dates, and coded data elements.
Depending on the data type, permissible values can be specified, such as minimum and maximum
values, or allowed values from a coding system.
Recommendation #11: Ensure and promote the use of standards in the registry system, (a) for diseases
classification such as ORPHANET and RD Ontology (ORDO) and (b) for phenotypes description (such as The
Human Phenotype Ontology (HPO). Use of standards facilitates data interoperability.
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Table 1. Existing international standards used in the biomedical field.
Area Standard Developer Website
Disease
ICD WHO http://www.who.int/classifications/icd/en/
ORDO ORPHANET http://www.orphadata.org/cgi-bin/inc/ordo_orphanet.inc.php/
Medical Nomenclature SNOMED SNOMED International https://www.snomed.org/snomed-ct
Phenotypic terms HPO Charité Berlin and with theMonarch Initiative http://human-phenotype-ontology.github.io/
Rare Clinical signs ICHPT IRDIRC http://www.irdirc.org/activities/current-activities/ichpt/
Medical and
administrative data HL7 http://www.hl7.org/implement/standards/index.cfm?ref=nav
Device GMDN GMDN Maintainance Agency https://www.gmdnagency.org/About/Database
Drugs
ATC DDD index WHO https://www.whocc.no/atc_ddd_index/
MEDDRA International Conference onHarmonisation (ICH) www.meddra.org
Adverse reactions WHO Art WHO https://www.who-umc.org/vigibase/services/learn-more-about-who-art/
Functioning ICF WHO http://www.who.int/classifications/icf/en/
Primary care ICPC-2 WHO http://www.who.int/classifications/icd/adaptations/icpc2/en/
Genes, genetic disorders OMIM
McKusick-Nathans Institute of
Genetic Medicine, Johns Hopkins
University School of Medicine
https://www.ncbi.nlm.nih.gov/omim
Laboratory and clinical
observations LOINC Regenstrief Institute https://loinc.org/
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5. IT Infrastructure Complying with FAIR Principles
The IT infrastructure of a registry is used to store and manage all the data that the registry collects.
The infrastructure should be easy to use by the registry managers, while at the same time secure and
flexible to adjust to changing requirements. These requirements are seemingly in conflict and hard
to implement. Therefore, it is important to select infrastructure in close collaboration with the IT
department, registry users, and organisations’ legal counsels (to verify that the chosen solutions will
meet the legal requirements set forth by the GDPR).
5.1. Infrastructure Selection and Implementation
The software chosen should closely match the registry’s requirements. It is tempting to choose a
home-built system that can closely match requirements; however, a new system will be expensive and
take a long time to implement, thus severely limiting registry’s ability to manage data. Therefore, it
is ideal to implement an existing system that offers ready-to-use solutions. Several commercial and
open source solutions are available for the same. Most of these systems offer easy customization of
databases based on CRFs and data elements. Using a system that can import and export data and
CRFs in a common standard format file such as CDISC ODM (Clinical Data Interchange Standards
Consortium Operational Data Model) [42], XML (Extensible Markup Language) [51] or CSV (Comma
Separated Values) [52] will provide a viable exit strategy if the chosen system is no longer sufficient for
needs of the registry.
International standards such as ISO 27001, ISO 27002 [53] for information data security set
requirements on the system’s security implementation. Legislations such as the GDPR [21] carry out
stiff penalties in case of data leakage. Commercial solutions often come with appropriate certifications
out of the box, but for systems that are not certified compliant out of the box, it is advisable to do a
security assessment during the implementation phase.
To ensure continuous availability of the system, there should be a regular system maintenance
plan that is maintained by the IT department. This plan should include the installation of relevant
updates and security patches, monitoring of system errors and unusual patterns, and a backup strategy
for data and systems consisting of a combination of regular full on-site and off-site encrypted backups.
Especially for smaller registries, if the local IT department does not have the capacity to maintain the
registry system, a hosted solution can be an alternative, provided that a data processor agreement
compliant with the GDPR is present.
5.2. FAIR Data Principles
Registry managers aim for registered data to be used as extensively and efficiently as possible
for the benefit of RD patients (within legal and ethical boundaries). Therefore, we consider not only
the quality of the content of a registry (i.e., the values), but also the quality of how data are made
available for wider use. Enabling efficient analysis of data across multiple registries and other data
sources is powerful and necessary in the RD domain, but poses specific requirements on how data
are made available. For instance, a researcher may wish to link known relations between treatments
and symptoms to patient-reported symptoms in a vascular anomaly registry. It would be inefficient to
re-collect information in the vascular anomaly registry that is already in Orphanet, and the linking
would be very inefficient and error-prone if Orphanet and the registry use different terms to describe
the same symptoms. Orphanet is one source of complementary information for a registry; a wealth
of information is available across health data registries and repositories around the world. While for
common diseases, ‘linkability’ of resources may be one of many priorities, for rare diseases it is a top
priority. To efficiently answer a question across all relevant resources by computer, it is important that
the sources use similar terminology for their values and data types. Data incompatibility has many
drawbacks for the rare disease domain, where resources are scarce compared to the number of diseases.
First, it creates an incentive to recollect data for every question again and again. Secondly, data
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researchers spend staggering amounts of time on repeatedly resolving incompatibilities and correcting
errors, because of the guesswork involved in determining what data from different resources exactly
mean. Thirdly, computers cannot aid in analysis across resources, because they depend on explicit,
unambiguous definitions of data. To mitigate this problem, we recommend ‘data stewardship’ at
the source and the application of the FAIR Guiding Principles for scientific data management and
stewardship [54], which have recently been accepted as an IRDiRC recognized resource. ‘FAIRification’
requires guidance and interdisciplinary collaboration. Disease knowledge is required to describe what
the data mean; information modelling expertise is required to encode data and make them available in
a machine-readable form. The resulting FAIR data landscape allows analysis to be carried out on data
at the source, even for sensitive data, while only sharing non-sensitive analysis results. The concept
pertains to straightforward queries, such as ‘Which biobank contains samples of the same phenotype
profile as those of my patient?’, to advanced computational analysis such as distributed machine
learning for medical decisions support (e.g., doi:10.1016/j.ijrobp.2017.04.021).
Recommendation #12: Involve registry users, the IT department and legal counsel in the selection process
for IT infrastructure. Select an off-the-shelf solution that is open and provides data exports in FAIR and common
open data formats. Conduct a security assessment as part of the implementation of your solution.
6. Data Quality
Data are the product of the registry system, and are the basis for the production of information
upon which decisions are made. The quality of data is defined by attributes such as completeness,
accuracy, timeless, usefulness, interoperability, accessibility, and data security [13]. All these attributes
are interrelated and it is important to define objectives for data quality and to find a good balance
among them. Several methods exist to quantify data completeness, e.g., capture-recapture, and linkage
with independent data sources. It is also important to state item completeness (% of missing values for
each variable), detect duplicate records (% of duplicate records found in the whole database), check
data accuracy (e.g., re-abstracting of data and evaluate % of agreement with external and independent
data sources), and assess reproducibility of data collection (e.g., % of agreement among data collectors).
In order to address data quality issues, most registries have introduced quality assurance and
quality control and quality assessment.
The quality process comprises of several aspects that can be categorized as quality assurance
(activities undertaken before data collection to ensure that the data are of the highest possible quality at
the time of collection), quality control (activities undertaken during and after data collection aimed at
identifying and correcting sources of data errors) and quality assessment (process of quality evaluation
of the whole registry system after having a consolidated database). Quality assurance, quality control
and quality assessment can be expensive and their costs associated need to be recognised and included
in the budget of the registry. In general, the higher level of completeness and accuracy are directly
linked to the costs.
Recommendations for assuring data quality include: (1) Clear-cut inclusion and non-inclusion
case criteria as well as target population should be defined; (2) analysis of sources of information
and their capacity of providing valid information should be explored; (3) case selection and case
ascertainment are the two most important questions to minimize selection bias; (4) control of duplicates
and minimizing mistakes in the interpretation and diagnosis are important clues for quality; (5) errors
in coding, data entry, and data transformation; data consistency across sites and over time; and
intentional errors should be taken care of while using electronic forms. Personnel should act as data
curators, and external audits should be conducted, among other mechanisms; (6) reliability and data
accuracy should be frequently explored; (7) data completeness must be checked.
Recommendation #13: In order to address data quality, introduce quality assurance and quality control
activities at different levels. Monitor the start of data collection and regulatory data quality at the central level
and locally (site monitoring). Produce regular data quality reports, including evaluation of different dimensions
of data quality (e.g., completeness, accuracy, duplicate prevention and timeless).
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7. Quality Information
Analysis is an essential activity aimed at converting data into information. Collection of high-quality
data is a prerequisite to producing correct and precise information, and a good statistical plan is needed
to produce accurate results. In fact, the utility of collected data relies on the quality of the data analysis
plan and the ability to interpret and disseminate the results [8].
Developing and checking transparent and consistent statistical analysis plans are activities related
to quality assurance and quality control activities in the framework of quality information of a registry.
The data collected by a registry could be used to undertake descriptive or analytical studies. In all
cases, it is important to develop a defined statistical analysis plan, describing statistical techniques to
be used in order to address the objective(s) of the registry. In the framework of quality of a registry,
descriptive analysis should be planned to ensure continuous monitoring. Epidemiological indicators
should be defined and calculated in order to detect trends and evaluate impacts.
Registries should be also designed keeping in mind that they serve as sources of data for
observational analytical studies, which aim to investigate the association of diseases to exposure.
Information about patient characteristics (i.e., gender, age) or known risk factors (i.e., socioeconomic
status) should be collected. Risk factors could also be associated with the investigated exposure
representing confounders or effect modifiers, and they have to be considered in the statistical
model [55]. Inclusion of variables regarding potential risk factors and accuracy of the collected
information are key points in performing an analytical observational study and limiting the bias
typical of this kind of study.
In order to facilitate a valid interpretation, the results of the analysis should be put into context
through comparisons with external evidence. Incidence, prevalence, rates, and any outcome of interest
should be compared to those obtained from other studies performed on different data sources, as
long as they are comparable. Interpretation should also offer reasons as to why results are similar or
different. In general, limiting the generalization of some types of results that await confirmation from
other studies is a strategy that credits scientifically to the registry and, consequently, to its quality.
Interpretation of the analyses offers recommendations to stakeholders (i.e., patient organizations,
health services researchers and providers, policy makers, drug agencies) to determine policy,
update information about disease course, choose a treatment or intervention, and develop clinical
practice guidelines.
Registries can provide such information through reports, which can be standardized according
to registry-specific aims and objectives. Registries report descriptive data, taking care of the quality
and validity of the information. The quality of a registry is closely associated with the validity of
information that is provided through reports and other forms of dissemination such as bulletins,
scientific papers and policy documents [25].
Recommendation #14: Develop a plan for statistical analysis describing the techniques to be used in order to
address the objective(s) of the registry. Ensure data dissemination to different stakeholders—registry participants,
patients, general public, decision makers, and researchers.
8. Documentation
Developing and maintaining transparent and adequate documentation on the registry is essential
for ensuring quality and efficient operation. The key document is the manual, which should contain
all types of explanations about registry functioning. Example of the list of documents contained in the
manual of operations are: Policy rules and governance; IT tools document; security document; ethic
rules; list of standard operating procedures; manual training; instructions for database users; data
elements/dictionary/standardisations; form templates (e.g., consent forms and patient information
notice); auxiliary tables (such as participating centers, declared user list) diagnosis tests, medical
proofs; classifications; personnel functions and tasks; budgets; checklists of list of activities to be
revised and marked after they have been developed by workers; nested research study protocols,
quality assessment document containing all procedures, control mechanisms and methods for correct
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evaluation of the registry and their frequency. A standard operating procedure is an important part
of this manual because it describes activities regarding data collection, cleaning, storing, monitoring,
reviewing, and reporting. Each procedure has to be clearly written, workflow well defined, and
involvement of each person clearly stated. In addition, a study protocol is a researcher’s blueprint
that guides and governs all aspects of how a study is conducted. It also provides transparency in
research, and improves the reproducibility and reusability of the research (complying with FAIR
data standards), thereby potentially increasing the credibility and validity of a study’s findings [56].
The details of manuals vary, depending on the complexity and objective of the registry. Last but not
least, documentation also supports transparency and follow up of all decisions made by the registry
governance (agenda and minutes of meetings, contractual documents and possible amendments, etc.).
Recommendation #15: Developing and maintaining transparent and adequate documentation is essential
for ensuring the quality and efficient operation of the registry. Documentation details may vary, depending on
the complexity of the registry.
9. Training
Training is another important aspect of registry quality. Training is not only important for registry
staff, but also for those of the healthcare units that provide the data.
The registry governance should provide a training plan to be provided on an ongoing basis,
subjected to review and updates, and needs to carefully consider how extensive the training should
be, who has to be trained (e.g., data providers, registry’s staff), what is the most appropriate way of
training, and if any supporting material is needed. In multi-centre registries, a central training session
is often the best way to ensure that all personnel is trained in a standardised manner.
Training is performed to provide knowledge on sources of information used in the registry;
methods of data collection; methods of data input and checks; sensitization on tasks, respective
obligations and responsibilities (e.g., carefully archiving patients’ informed consents); statistical
analysis of data; linkage procedures; validation procedures; review of clinical events; standardization
of procedures and methods for evaluation of quality of data; and most importantly to ensure that
procedures adopted to generate high-quality data are implemented and understood in practice.
Training should be performed regularly or when updates or changes occur (changes to the data
collection system; personnel, software for data entry and data element). Training activities lead to cost
reduction over time.
Recommendation #16: Ensure proper and systematic training of registry staff and data providers at all
levels. Provide training in a systematic way prior registry access by new users, and when changes occur.
10. Data Quality Audit
Data quality audits are independent systematic examinations of data that establish the extent to
which registry data conform to predetermined standards or criteria.
Audits vary in scope, frequency and location, depending on the objectives of a registry and
funding constraints.
An audit can be conducted on a random sample of participating sites (e.g., 5 to 20 percent of
registry sites); and “for cause” (meaning only when there is an indication of a problem, such as one site
being an outlier compared to most others) [8]. It can be conducted either on the whole set of data of
the registry, or just for a select (random or systematic) sample of patients, using sampling techniques.
Data should be collected in a manner that facilitates auditing.
The approach to auditing the quality of the data should reflect the most significant sources of
error, with respect to the purpose of the registry.
The audit can assess enrolment of eligible patients, and quality of data (e.g., evaluation of
data completeness or accuracy of diagnosis). It should also review records to ensure that all study
procedures are being implemented and followed. Data audit can be performed by visiting the
participating centers and comparing a sample of the data from the central registry database with
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the original source data. When an audit identifies serious problems, the leaders may decide to exclude
that data from the overall results.
The audit can be internal or external. Internal audit is carried out by the registry staff, following a
concrete plan and using specific indicators to assess the most significant sources of error. External audit
is performed by external personnel, in accordance with pre-established criteria [6].
Subsequent to audits, the findings should be communicated to all staff, indicating the areas for
improvement and highlighting good practice in order to facilitate learning.
Recommendation #17: Have in place an audit system, which includes defined triggers that initialize
the process.
11. Conclusions
The development of RD registries is seeing considerably growth, as the field deals with a scarcity
of patients, and the need to gather cohort data to enable research, better define natural history and
epidemiology, facilitate clinical research studies, and assess healthcare standards.
In this article, we discussed the essential aspects influencing registry quality. A list of recommendations
was reported in Table 2 and elaborated upon.
Recommendations made by experts were focused on, which included the establishment of registry
governance, identification of correct data sources, specification of data elements, case report forms,
standardisations, construction of a IT infrastructure complying with FAIR principles, production of
data quality, and dissemination of quality information. Other topics, such as developing adequate
documentation, training of staff and providing data quality audit, are also considered essential for
improving registry quality.
It is hoped that these recommendations can help registry owners and curators facilitate self-quality
assessments to operate and maintain high-quality registries. Future work in this field includes
developing a toolkit based on process indicators to check the quality of existing registries, and provide
a score and feedback on aspects of the registry that require improvement.
In conclusion, in the field of RD registries, there is a need for coordination between ongoing
initiatives at the national and international levels. At the national level, we recommend the development
of a centralized, public, national, “registry-as-a-service” platform, which will guarantee access to
highly-trained staff on all topics mentioned in the article, foster the standardisation of registries, allow
economy of cost and time for setting up new registries, allow interlinking of key data sources on
different diseases, and increase the capacity to develop cooperation at the regional level (Europe, in this
case). At the national level, platforms for RD registries in Europe have been collaborating to create a
centralized European Union framework on patient registries that offer data sharing, reduce duplication
of efforts and costs, facilitate validation of results, enable engagement with experts and the patient
community, and overcome the “rare disease problem” in terms of cohort size, powering trials, and
finding confirmatory cases.
Int. J. Environ. Res. Public Health 2018, 15, 1644 18 of 22
Table 2. List of recommendations for Improving the Quality of Rare Disease Registries.
Topics Recommendations
Registry definition
#1 RD registries are organised information system, based on observational study designs with one or several predefined purposes and rules with a long-term
perspective. We recommend that RD registries should not be limited by geographical area but have an international vision. In the field of RD, there is a need to
identify as many patients as possible, and significant number of cases could be identified from a large population. Moreover, RD registries should be created and
used as a data source for the purpose of performing subsequent or additional studies related to research, patient care or public health monitoring.
Registry classification #2 In order to fulfil the expected objectives, the taxonomic position of the registry should be clearly defined. It can be classified into several categories according todifferent criteria (e.g., geographical coverage, diseases coverage, type of sponsors, methods used for data collection etc.).
Governance
#3 Define clear objectives and design the structure of the database consequently. Often registries start with a single purpose, but can evolve into multi-purposes,
addressing the interests of other collaborators and stakeholders. In RD registries objectives should be expanded but it is preferable to prioritise and define them
clearly.
#4 Engage with all relevant stakeholders, especially patient representatives at an early stage in the implementation of a registry.
#5 Establish a good registry team with clear role and responsibilities for all staff working members in proportion with the registry’s size, ambition and objectives.
Identify a registry leader, domain expert, IT expert and ELSI expert from the start. Either employ an IT person within your registry or setup a long-term
partnership with a commercial company.
#6 Ensure compliance with (inter-) national and local ethical and legal requirements and on that basis develop public policies for accessing maintaining and
operating the registry.
#7 Ensure that the start-up required budgets have been evaluated and that the registry is well resourced for a pre-defined period. For long-term sustainability,
registries should to seek funding from multiple, complementary sources.
Data Source
#8 The selection of primary data sources are critical for the success of the registry; they provide data of higher quality than secondary data sources; before
incorporating a secondary data source into a registry, it is important to consider the legal and ethical feasibility of its incorporation and the potential impact of the
data quality of the secondary data source on the overall data quality of the registry. Primary data sources are expensive and time consuming, so you should
consider the possibility of reuse of existing data from secondary sources.
#9 Provide clear-cut definition of the inclusion and non-inclusion criteria. In terms of geographical coverage, when selecting data sources (e.g., hospitals), it is
important to consider the representativeness and ensure a satisfying level of quality in identifying all eligible patients (including the ability of proper follow-up).
Data Elements, Case
Report Form,
Standardisations
#10 The following steps are recommended for defining Data Elements:
• Determine what data are needed for the purpose(s) of the registry.
• Determine what information models and forms exist that can be reused.
• Determine what data are obtained from primary sources (requiring additional effort to collect) and from secondary sources (at the risk of lower data quality).
• Determine what data can be derived from other data, rather than being collected separately.
• Determine whether data can be collected and stored as part of routine clinical care (thus becoming data from secondary source).
• Determine whether data can be fed back to assist clinical care.
#11 Ensure and promote the use of standards in the registry system (a) for diseases classification such as ORPHANET and RD Ontology (ORDO) and (b) for
phenotypes description (such as The Human Phenotype Ontology (HPO). Use of standards facilitates the data interoperability.
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Table 2. Cont.
Topics Recommendations
IT Infrastructure complying
with FAIR principles
#12 Involve registry users, the IT department and legal counsel in the selection process for the IT infrastructure. Select an off-the-shelf solution that is open
and provides data exports in FAIR and common open data formats. Conduct a security assessment as part of the implementation track of your solution.
Data Quality
#13 In order to address data quality, introduce quality assurance and quality control activities at different levels. Monitor from the start of data collection
and then regulatory data quality at central level and locally (site monitoring); produce regular data quality reports including evaluation of different
dimensions of data quality (e.g., completeness, accuracy, duplicate prevention and timeless).
Quality information #14 Develop a plan for statistical analysis describing the statistical techniques to be used in order to address the objective(s) of the registry; ensure datadissemination to different stakeholders: registry participants’, patients, general public, decision makers and researchers.
Documentation #15 Developing and maintaining transparent and adequate documentation is essential for ensuring the quality and efficient operation of the registry.The detail of documentation may vary from registry to registry depending on the complexity of the registry.
Training #16 Ensureproper and systematic training at all levels, addressed to registry staff and data providers. Provide training in a systematic way prior registryaccess by new users and when changes occur.
Data quality audit #17 Have an audit system including defined triggers initializing audit processes.
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